Halozyme Therapeutics Granted Preliminary Injunction From German Court Against Merck's Keytruda

Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme), announced today that a German court has granted its request for a preliminary injunction ordering Merck to refrain from distributing and offering Keytruda SC in Germany.

The Munich Regional Court's 7th Civil Division found that there is imminent infringement for Keytruda SC in Germany regarding one of Halozyme's MDASE™ patents in Europe, European Patent No. 2 797 622 (EP 622). As a consequence, Merck's launch activities for Keytruda SC in Germany that are within the scope of the order must be halted. Although the preliminary injunction decision is appealable, Halozyme believes the order will withstand attack if appealed. Separate nullity proceedings against this patent initiated by Merck in August 2025 are pending before the German Federal Patent Court.

Importantly, patients who want to use Keytruda will have access to the IV version of Keytruda, which is not covered by Halozyme's patent or the court's injunction order.